bioMérieux Shares Fall 2.79% Midday Amid Technical Pressure
On Wednesday, January 28, bioMérieux shares recorded a significant decline of 2.79%, reaching 99.15 euros from 102 euros the previous day. This downturn is part of a longer-term bearish trend, with the in vitro diagnostics specialist showing a decrease of 4.3% over the week and 12.26% over three months. On the same day, BNP Paribas Exane maintained a neutral stance on the stock, while Invest Securities had upgraded its recommendation to buy in November 2025 with a target set at 124 euros.
Technical Analysis Highlights Critical Situation
Graphical analysis reveals a critical situation for bioMérieux. The RSI has plunged to an exceptionally low level of 9, indicating a deep oversold zone rarely seen, reflecting intense selling pressure. The stock is now significantly below its key moving averages, at 107.96 euros for the MM20 and 107.66 euros for the MM50, forming a short-term technical resistance. The MACD configuration heightens concerns: with a line at -1.44 and a negative histogram at -0.84, the indicator confirms the lack of bullish momentum. The breach of the psychological support threshold of 102 euros is an additional signal of technical weakness. However, the price remains above the lower Bollinger band set at 100.04 euros, which could provide a short-term floor. The monthly volatility remains contained at 5.77 with a very low beta of 0.12, showing relative independence from general market movements.
Analyst Recommendations Suggest Significant Recovery Potential
Analyst recommendations indicate a substantial recovery potential. Invest Securities' target of 124 euros implies a 25% increase from the current price, reflecting confidence in the Lyon-based group's prospects. This outlook is based on the fundamentals of the third quarter of 2025, during which the group generated a revenue of 2,992 million euros over nine months with an organic growth of 7.3%. However, management has revised its annual ambitions, adjusting the organic growth forecast between 5.5% and 6.5% due to a late respiratory season, while still expecting an increase in contributory operating income between 12% and 18%. This downward revision notably reflects an 8% decrease in BIOFIRE respiratory panel sales in the third quarter due to low epidemiological activity. Meanwhile, the group has completed the acquisition of Accellix for 35 million euros, strengthening its position in the quality control of cellular and gene therapies.
